| aminoglutethimide vs hydrocortisone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 1.10 [0.39 3.13] | p=1.00 | 0 | 61 | 1 | Mercer, | | objective response (ORR) | 1.41 [0.31 6.53] | p=1.00 | 0 | 61 | 1 | Mercer, | | hot flushes | no data | | rash | no data | | vaginal bleeding | no data | | thromboembolic AE | no data | | arthralgia | no data | | vomiting | no data | | diarrhoea | no data | | nausea | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| aminoglutethimide vs medroxyprogesterone acetate | No demonstrated result rash by 2714% (harmful effect) suggested hot flushes by 77% (not demonstrated) suggested vaginal bleeding by 85% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 1.04 [0.82 1.31] | p=1.00 | 0 | 1140 | 3 | Canney,Garcia-Giralt,Samonis, | | objective response (ORR) | 1.17 [0.91 1.51] | p=1.00 | 0 | 1140 | 3 | Canney,Garcia-Giralt,Samonis, | | hot flushes | 0.23 [0.06 0.81] | p=0.04 | 0 | 218 | 1 | Canney, | | rash | 28.14 [3.65 216.93] | p=0.04 | 0 | 271 | 2 | Canney,Samonis, | | vaginal bleeding | 0.15 [0.03 0.86] | p=0.04 | 0 | 271 | 2 | Canney,Samonis, | | thromboembolic AE | no data | | arthralgia | no data | | vomiting | no data | | diarrhoea | no data | | nausea | 7.27 [0.36 148.37] | p=1.00 | 0 | 53 | 1 | Samonis, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| aminoglutethimide vs megestrol acetate | No demonstrated result rash by 1276% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 0.92 [0.51 1.67] | p=1.00 | 0 | 176 | 1 | Lundgren, | | objective response (ORR) | 0.68 [0.37 1.26] | p=1.00 | 0 | 331 | 2 | Lundgren,Russell, | | death (overall survival) | 0.89 [0.40 2.00] | p=1.00 | 0 | -18 | 1 | Russell, | | progression or death (progression free survival PFS) | 1.25 [0.57 2.75] | p=1.00 | 0 | -18 | 1 | Russell, | | hot flushes | no data | | rash | 13.76 [3.70 51.13] | p=0.04 | 0 | 353 | 2 | Lundgren,Russell, | | vaginal bleeding | no data | | thromboembolic AE | 1.01 [0.14 7.34] | p=1.00 | 0 | 177 | 1 | Russell, | | arthralgia | no data | | vomiting | no data | | diarrhoea | no data | | nausea | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| aminoglutethimide vs tamoxifen | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 0.92 [0.57 1.48] | p=1.00 | 0 | 311 | 2 | Alonso-Munoz,Gale, | | objective response (ORR) | 0.74 [0.46 1.19] | p=1.00 | 0 | 311 | 2 | Alonso-Munoz,Gale, | | death (overall survival) | 1.12 [0.51 2.45] | p=1.00 | 0 | -18 | 1 | Gale, | | progression or death (progression free survival PFS) | 0.84 [0.41 1.70] | p=1.00 | 0 | -18 | 1 | Gale, | | hot flushes | no data | | rash | no data | | vaginal bleeding | no data | | thromboembolic AE | no data | | arthralgia | no data | | vomiting | no data | | diarrhoea | no data | | nausea | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| aminoglutethimide + tamoxifen vs tamoxifen | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 0.87 [0.40 1.92] | p=1.00 | 0 | 100 | 1 | Ingle, | | objective response (ORR) | 1.24 [0.56 2.73] | p=1.00 | 0 | 100 | 1 | Ingle, | | death (overall survival) | 0.79 [0.30 2.11] | p=1.00 | 0 | -18 | 1 | Ingle, | | progression or death (progression free survival PFS) | 0.85 [0.33 2.17] | p=1.00 | 0 | -18 | 1 | Ingle, | | vaginal bleeding | no data | | thromboembolic AE | no data | | arthralgia | no data | | hot flushes | NaN [NaN NaN] | p=1.00 | 0 | 97 | 1 | Ingle, | | rash | NaN [NaN NaN] | p=1.00 | 0 | 94 | 1 | Ingle, | | vomiting | no data | | diarrhoea | no data | | nausea | 2.16 [0.90 5.15] | p=1.00 | 0 | 94 | 1 | Ingle, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| combination of hormone therapies vs tamoxifen | No demonstrated result rash by 1500% (harmful effect) nausea by 170% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| clinical benefit | 0.82 [0.48 1.40] | p=1.00 | 0 | 222 | 1 | Powles, | | objective response (ORR) | 0.71 [0.41 1.23] | p=1.00 | 0 | 222 | 1 | Powles, | | hot flushes | no data | | vaginal bleeding | no data | | thromboembolic AE | no data | | arthralgia | no data | | rash | 16.00 [2.08 122.91] | p=0.04 | 0 | 222 | 1 | Powles, | | vomiting | 2.50 [0.76 8.23] | p=1.00 | 0 | 222 | 1 | Powles, | | diarrhoea | 11.00 [0.60 201.40] | p=1.00 | 0 | 222 | 1 | Powles, | | nausea | 2.70 [1.24 5.90] | p=0.04 | 0 | 222 | 1 | Powles, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
